Definium Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results. Also, Piper Sandler lowered its price target on the stock from $49 to $48.

Benzinga Newsdesk www.benzinga.com Negative 96.2%

Neg 96.2% Neu 0% Pos 0%

Comments

No comments yet. Be the first!